AC Immune

$6.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.25 (+4.22%) Today

$0.00 (0.00%) As of 9:04 PM UTC after-hours

Why Robinhood?

You can buy or sell AC Immune and other stocks, options, and ETFs commission-free!

About ACIU

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland. The listed name for ACIU is AC Immune SA Common Stock.

CEO

Andrea Pfeifer

Employees

132

Headquarters

Lausanne, Vaud

Founded

2003

Market Cap

433.60M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

507.77K

High Today

$6.30

Low Today

$5.85

Open Price

$6.08

Volume

171.65K

52 Week High

$13.00

52 Week Low

$4.07

Collections

ACIU Earnings

-$0.28

-$0.10

$0.08

$0.26

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 29, Pre-Market